ARTICLE | Regulation

U.K.’s severe COVID-19 patients gain early access to remdesivir, at no cost to NHS

May 27, 2020 2:10 AM UTC

The U.K. will make remdesivir available to patients with severe COVID-19 before Gilead’s antiviral is officially approved.

Gilead Sciences Inc. (NASDAQ:GILD) will provide remdesivir to the U.K.’s NHS free of charge throughout the Early Access to Medicines Scheme (EAMS) period, which lasts for a year...

BCIQ Company Profiles

Gilead Sciences Inc.